Abstract：
BACKGROUND: Cancer caused an estimated 2.2 million deaths across Europe in 2020. This analysis estimated the cost of lost productivity due to premature deaths associated with lung, breast and melanoma cancer and investigated the temporal trends across European regions across 2010, 2015 and 2019.
METHODS: The human capital approach was used to estimate the indirect costs from lung, melanoma, and breast cancers (ICD-10 code: C33-34, C43, and C50, respectively) in Northern, Eastern, Southern, and Western Europe. Age-specific mortality, and country-specific wages and employment rates were used to calculate years of productive life lost (YPLL), YPLL/death and present value of future lost productivity (PVFLP). Data were sourced from the World Health Organization, Eurostat, and the World Bank.
RESULTS: The number of cancer deaths remained relatively stable from 2010-2019. YPLL/death decreased across all European regions and for all cancers between 2010-2019 (reported ranges across European regions; lung cancer: 25-42%; breast cancer: 18-21%; melanoma: 31-37%). In Europe, the decrease in PVFLP in 2019 compared to 2010 was €2,995M for lung cancer, €295M for melanoma, and €466M for breast cancer, with an overall reduction of productivity cost of €3,756M in these cancer types.
CONCLUSIONS: The results from this study illustrate a decreased trend in productivity costs from 2010-2019 which could be driven by deaths occurring at an older age, suggesting that advances in cancer prevention and the treatment landscape have extended the life of cancer patients, yielding less productivity losses.
UNASSIGNED: The indirect economic costs modelled show the impact of past effective health policies and new treatments. Continued efforts to improve public health policies in supporting public awareness of risk factors and value of early diagnosis could lead to further reduction in these losses. Prevention, early diagnosis, and activation of early treatment pathways could serve to reduce loss of life and improve productivity.
METHODS: The human capital approach was used to estimate the indirect costs from lung, melanoma, and breast cancers (ICD-10 code: C33-34, C43, and C50, respectively) in Northern, Eastern, Southern, and Western Europe. Age-specific mortality, and country-specific wages and employment rates were used to calculate years of productive life lost (YPLL), YPLL/death and present value of future lost productivity (PVFLP). Data were sourced from the World Health Organization, Eurostat, and the World Bank.
RESULTS: The number of cancer deaths remained relatively stable from 2010-2019. YPLL/death decreased across all European regions and for all cancers between 2010-2019 (reported ranges across European regions; lung cancer: 25-42%; breast cancer: 18-21%; melanoma: 31-37%). In Europe, the decrease in PVFLP in 2019 compared to 2010 was €2,995M for lung cancer, €295M for melanoma, and €466M for breast cancer, with an overall reduction of productivity cost of €3,756M in these cancer types.
CONCLUSIONS: The results from this study illustrate a decreased trend in productivity costs from 2010-2019 which could be driven by deaths occurring at an older age, suggesting that advances in cancer prevention and the treatment landscape have extended the life of cancer patients, yielding less productivity losses.
UNASSIGNED: The indirect economic costs modelled show the impact of past effective health policies and new treatments. Continued efforts to improve public health policies in supporting public awareness of risk factors and value of early diagnosis could lead to further reduction in these losses. Prevention, early diagnosis, and activation of early treatment pathways could serve to reduce loss of life and improve productivity.
摘要：
背景：在2020年，癌症在整个欧洲造成约220万人死亡。该分析估计了由于与肺相关的过早死亡而导致的生产力损失的成本，乳腺癌和黑色素瘤，并调查了2010年、2015年和2019年欧洲地区的时间趋势。
方法：人力资本方法用于估计来自肺部的间接成本，黑色素瘤，和乳腺癌（ICD-10代码：C33-34，C43和C50，分别）在北部，东方,南方,和西欧。特定年龄死亡率，并使用特定国家的工资和就业率来计算生产寿命损失年数(YPLL)，YPLL/死亡和未来生产力损失的现值(PVFLP)。数据来自世界卫生组织，欧统局,和世界银行。
结果：2010-2019年癌症死亡人数保持相对稳定。2010-2019年间，所有欧洲地区和所有癌症的YPLL/死亡人数均下降（欧洲地区报告范围；肺癌：25-42％；乳腺癌：18-21％；黑色素瘤：31-37％）。在欧洲,2019年与2010年相比，肺癌的PVFLP减少了2995亿欧元，2.95亿欧元用于黑色素瘤，乳腺癌4.66亿欧元，在这些癌症类型中，生产力成本总体降低了375.6亿欧元。
结论：这项研究的结果表明，从2010年到2019年，生产力成本呈下降趋势，这可能是由老年人死亡造成的。表明癌症预防和治疗领域的进步延长了癌症患者的寿命，产生更少的生产力损失。
■建模的间接经济成本显示了过去有效的卫生政策和新疗法的影响。继续努力改善公共卫生政策，以支持公众对风险因素和早期诊断价值的认识，可以进一步减少这些损失。预防,早期诊断,和激活早期治疗途径可以减少生命损失和提高生产力。
方法：人力资本方法用于估计来自肺部的间接成本，黑色素瘤，和乳腺癌（ICD-10代码：C33-34，C43和C50，分别）在北部，东方,南方,和西欧。特定年龄死亡率，并使用特定国家的工资和就业率来计算生产寿命损失年数(YPLL)，YPLL/死亡和未来生产力损失的现值(PVFLP)。数据来自世界卫生组织，欧统局,和世界银行。
结果：2010-2019年癌症死亡人数保持相对稳定。2010-2019年间，所有欧洲地区和所有癌症的YPLL/死亡人数均下降（欧洲地区报告范围；肺癌：25-42％；乳腺癌：18-21％；黑色素瘤：31-37％）。在欧洲,2019年与2010年相比，肺癌的PVFLP减少了2995亿欧元，2.95亿欧元用于黑色素瘤，乳腺癌4.66亿欧元，在这些癌症类型中，生产力成本总体降低了375.6亿欧元。
结论：这项研究的结果表明，从2010年到2019年，生产力成本呈下降趋势，这可能是由老年人死亡造成的。表明癌症预防和治疗领域的进步延长了癌症患者的寿命，产生更少的生产力损失。
■建模的间接经济成本显示了过去有效的卫生政策和新疗法的影响。继续努力改善公共卫生政策，以支持公众对风险因素和早期诊断价值的认识，可以进一步减少这些损失。预防,早期诊断,和激活早期治疗途径可以减少生命损失和提高生产力。
